Drug profile · INN
glipizide
MELIZIDE
glipizide (MELIZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — glipizide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
glipizide (MELIZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sulfonylurea receptor 1, Kir6.2 blocker
Primary target: Sulfonylurea receptor 1, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is glipizide?
glipizide (MELIZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glipizide?
MELIZIDE is a marketed brand name for glipizide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glipizide?
glipizide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.